Kazuhiro Sakamoto

发表

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Masahiko Ando, Kazuhiro Asami, Masaaki Fukuda, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR

Masahiko Ando, Seiichi Kakegawa, Akihito Kubo, 2015, Clinical Cancer Research.